Monopar Therapeutics (MNPR) Return on Equity (2018 - 2020)

Monopar Therapeutics' Return on Equity history spans 3 years, with the latest figure at 0.37% for Q3 2020.

  • For Q3 2020, Return on Equity rose 46.0% year-over-year to 0.37%; the TTM value through Sep 2020 reached 0.37%, up 46.0%, while the annual FY2019 figure was 0.44%, 4.0% down from the prior year.
  • Return on Equity for Q3 2020 was 0.37% at Monopar Therapeutics, up from 0.37% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.32% in Q1 2020 and bottomed at 2.03% in Q2 2018.
  • The 3-year median for Return on Equity is 0.5% (2019), against an average of 0.77%.
  • The largest YoY upside for Return on Equity was 127bps in 2019 against a maximum downside of -43bps in 2019.
  • A 3-year view of Return on Equity shows it stood at 0.46% in 2018, then decreased by -9bps to 0.5% in 2019, then rose by 26bps to 0.37% in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Return on Equity are 0.37% (Q3 2020), 0.37% (Q2 2020), and 0.32% (Q1 2020).